Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN
Preoperative Immune Checkpoint Inhibitor Therapy for Patients With Primary Untreated or Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (RM-SCCHN)
Sponsor: Bristol-Myers Squibb
This PHASE2 trial investigates Head and Neck Cancer and Head and Neck Cancer Metastatic and is currently completed. Bristol-Myers Squibb leads this study, which shows 13 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
13 versions recorded-
Dec 2024 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Dec 2024 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Mar 2024 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Feb 2024 — Mar 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 8 earlier versions
-
Feb 2023 — Feb 2024 [monthly]
Active Not Recruiting PHASE2
-
Mar 2022 — Feb 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Mar 2021 — Mar 2022 [monthly]
Recruiting PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Jan 2020 — Mar 2020 [monthly]
Recruiting PHASE2
-
Sep 2019 — Jan 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Apr 2019 — Sep 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
For direct contact, visit the study record on ClinicalTrials.gov .